BioCentury
ARTICLE | Company News

Ablynx, Merck Serono in Nanobodies deal

September 5, 2008 1:53 AM UTC

Ablynx (Euronext:ABLX) and Merck Serono partnered to co-discover and co-develop Ablynx's Nanobodies against two undisclosed targets in cancer and immunology. Ablynx will receive EUR 10 million ($14.6 ...